3202-35-5

Basic information

• Product Name: 4-(3-FLUORO-PHENOXY)-PIPERIDINE
• Synonyms: 4-(3-FLUORO-PHENOXY)-PIPERIDINE;CHEMBRDG-BB 4004482;4-(3-fluorophenoxy)piperidine(SALTDATA: HCl)
• CAS NO: 3202-35-5
• Molecular Formula: C₁₁H₁₄FNO
• Molecular Weight: 195.23
• Mol File: 3202-35-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 270.4°C at 760 mmHg
• Flash Point: 117.3°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 0.00686mmHg at 25°C
• Refractive Index: 1.51
• PKA: 9.68±0.10(Predicted)
• CAS DataBase Reference: 4-(3-FLUORO-PHENOXY)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-FLUORO-PHENOXY)-PIPERIDINE(3202-35-5)
• EPA Substance Registry System: 4-(3-FLUORO-PHENOXY)-PIPERIDINE(3202-35-5)

Safety Data

• Hazardous Substances Data: 3202-35-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H14FNO/c12-9-2-1-3-11(8-9)14-10-4-6-13-7-5-10/h1-3,8,10,13H,4-7H2

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 372-20-3 3-fluorophenol 
• 920511-29-1 1,1-dimethylethyl 4-((3-fluorophenyl)oxy)-1-piperidinecarboxylate 

Downstream Products

• 3202-36-6 4-(3-fluorophenoxy)piperidine hydrogen chloride salt 

Relevant articles and documents

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

COMPOUNDS

The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders.

PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS

The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, (I) wherein R1, R2, R3, R4, R5, R6, Z, X and B are as defined in the specification. The compounds are partial or full agonists at the GPR38 receptor. Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.